VANI - NASDAQ

Vivani Medical, Inc.

VANI·NASDAQ

$1.28

-0.78%

HealthcareMedical - Devices

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$75.62M

EPS-0.4300

P/E Ratio-2.98

Earnings Date08/12/2026

39.39M

Assets

-5%

3Y-23.0%

5Y+655.0%

10Y+134.0%

23.66M

Total Liabilities

-1%

3Y+247.0%

5Y+624.0%

10Y+318.0%

15.73M

Total Equity

-11%

3Y-64.0%

5Y+707.0%

10Y+41.0%

Vivani Medical, Inc. Funding & Solvency Profile

VANI · NASDAQ

Current Assets

Cash & Cash Equivalents16.23M

Net Receivables654.00K

Inventory0.00

Other Current Assets1.01M

Total Current Assets18 M

Non-Current Assets

Property, Plant & Equipment20.11M

Goodwill & Intangible Assets0.00

Long-Term Investments1.34M

Other Non-Current Assets48.00K

Total Non-Current Assets21 M

Total Assets

39.39M

Financial Health Analysis

Current Ratio

2.71x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.50x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

11 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

45% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Vivani Medical, Inc. Balance Sheet

VANI • NASDAQ

Vivani Medical, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	16.2M	18.4M	20.7M	45.1M	2.2M	2.1M	11.3M	4.5M	7.8M	10.9M	16M	619.4K	62.6K	144.8K
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2M	10.3M	15.7M	34M	8.6M	4.3M
Cash & Short-Term Investments	16.2M	18.4M	20.7M	45.1M	2.2M	2.1M	11.3M	4.5M	7.8M	10.9M	16M	34.6M	8.7M	4.5M
Net Receivables	654K	253K	0.0	0.0	0.0	0.0	455K	504K	1.8M	274K	1.5M	707.6K	468.6K	367.9K
Accounts Receivables	0.0	253K	0.0	0.0	0.0	0.0	455K	504K	1.8M	274K	1.5M	707.6K	468.6K	320.3K
Other Receivables	654K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	47.6K
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	1M	3.3M	2.7M	3.4M	8.2M	5.7M	2.3M	1.8M
Prepaids	0.0	0.0	0.0	2.5M	291K	348K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	1M	1.8M	2.4M	0.0	0.0	0.0	299K	1.4M	795K	717K	1.1M	927.6K	298.2K	265.9K
Total Current Assets	17.9M	20.4M	23.1M	47.5M	2.5M	2.4M	13.1M	9.6M	13.2M	15.3M	26.8M	42M	11.8M	7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	20.1M	19.7M	21.3M	2M	2.8M	2.6M	3.5M	1M	1.3M	1.5M	1.4M	1M	723.5K	793.2K
Long-Term Investments	1.3M	1.3M	1.3M	0.0	0.0	0.0	0.0	0.0	0.0	2K	5K	0.0	0.0	0.0
Other Non-Current Assets	48K	131K	52K	1.6M	200K	200K	25K	37K	33K	39K	49K	88.6K	162.1K	160.3K
Total Non-Current Assets	21.5M	21.1M	22.7M	3.6M	3M	2.8M	3.5M	1.1M	1.3M	1.5M	1.5M	1.1M	885.6K	953.6K
Total Assets	39.4M	41.6M	45.8M	51.1M	5.5M	5.2M	16.6M	10.7M	14.5M	16.8M	28.3M	43.1M	12.7M	8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1M	817K	542K	1.2M	281K	223K	1.1M	1.3M	752K	1.2M	710K	513.1K	314.3K	731.4K
Accounts Payable	1M	817K	542K	1.2M	281K	223K	1.1M	1.3M	752K	1.2M	710K	513.1K	314.3K	731.4K
Accrued Expenses	0.0	3.5M	3.4M	4.3M	895K	573K	2.7M	2.7M	2.6M	1.6M	2.1M	1.4M	1.1M	862.2K
Short Term Debt	1.8M	0.0	0.0	0.0	0.0	637K	237K	0.0	0.0	0.0	0.0	0.0	0.0	52.9K
Capital Lease Obligations (Current)	0.0	1.3M	1.4M	955K	910K	752K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	335K	167K	48K	85K	322K	4.7M	68.9K	167.3K
Other Current Liabilities	3.8M	343K	396K	385K	0.0	0.0	2.6M	3.4M	3.2M	2.8M	4.9M	6M	1.2M	949.1K
Total Current Liabilities	6.6M	6M	5.7M	6.8M	2.1M	2.2M	7M	7.6M	6.6M	5.7M	8M	8.5M	2.7M	2.8M
NON-CURRENT LIABILITIES
Long Term Debt	17.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.2M	8.3M
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	17.1M	18M	19.3M	0.0	902K	1.1M	2.4M	0.0	0.0	0.0	0.0	0.0	19.2M	8.3M
Capital Lease Obligations	0.0	19.3M	20.7M	955K	1.8M	1.8M	2.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	23.7M	24M	25M	6.8M	3M	3.3M	9.3M	7.6M	6.6M	5.7M	8M	8.5M	21.9M	11M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	448K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	8K	6K	5K	5K	54.6M	43M	264M	229M	202.2M	186.8M	166M	163.2M	88.3M	85.6M
Additional Paid-In Capital	164.2M	139.5M	119.1M	117.1M	6.7M	5M	0.0	44.1M	0.0	30.7M	27.3M	0.0	0.0	0.0
Retained Earnings	-148.5M	-121.9M	-98.4M	-72.8M	-58.9M	-46.1M	-304.8M	-269.5M	-234.4M	-205.9M	-172.7M	-152.7M	-117.5M	-94.5M
Accumulated Other Comprehensive Income/Loss	30K	48K	140K	35K	0.0	-448K	-562K	-575K	-419K	-455K	-376K	-474K	-267.5K	-185.1K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	48.6M	0.0	40.5M	0.0	0.0	24.6M	20.2M	6.1M
Total Stockholders' Equity	15.7M	17.6M	20.8M	44.3M	2.5M	2M	7.3M	3.1M	7.9M	11.2M	20.3M	34.6M	-9.2M	-3M
Total Equity	15.7M	17.6M	20.8M	44.3M	2.5M	2M	7.3M	3.1M	7.9M	11.2M	20.3M	34.6M	-9.2M	-3M
SUMMARY
Total Liabilities & Equity	39.4M	41.6M	45.8M	51.1M	5.5M	5.2M	16.6M	10.7M	14.5M	16.8M	28.3M	43.1M	12.7M	8M
Total Investments	1.3M	1.3M	1.3M	0.0	0.0	0.0	0.0	0.0	7.2M	2K	5K	34M	8.6M	4.3M
Total Debt	18.9M	19.3M	20.7M	955K	1.8M	2.5M	2.6M	0.0	0.0	0.0	0.0	0.0	19.2M	8.3M
Net Debt	2.6M	961K	42K	-44.1M	-366K	386K	-8.7M	-4.5M	-7.8M	-10.9M	-16M	-619.4K	19.1M	8.2M
Shares Outstanding	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903	59,243,903

SEC Filings

VANI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 29, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 27, 2026	January 25, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 13, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 28, 2025	October 26, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 03, 2025	October 03, 2025	2025	View Filing

Showing 1 to 10 of 304 filings

Related Guides

Blog Categories

Continue your VANI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.